Do vitamin B12 and folate deficiencies raise homocysteine levels?

The biochemical link between vitamin B12, folate, and homocysteine regulation is robustly established through precise metabolic pathways.

Mechanistic pathway

• The remethylation of homocysteine to methionine is catalyzed by cytosolic methionine synthase (MTR). This reaction is strictly dependent on methylcobalamin (active vitamin B12) as an essential cofactor and 5-methyltetrahydrofolate (5-MTHF, the primary active folate) as the methyl group donor.
• A deficiency in vitamin B12 inactivates MTR, trapping folate as 5-MTHF (known as the "methyl trap"). This metabolic blockade halts the regeneration of methionine and its downstream activation product S-adenosylmethionine (SAM), the cell's primary methyl donor, while causing upstream homocysteine to accumulate.

Clinical evidence and implications

• Deficiencies in either B12 or folate consistently result in hyperhomocysteinemia due to impaired remethylation, making elevated plasma homocysteine a highly sensitive functional biomarker for tissue-level B-vitamin depletion.
• Clinical interventions using targeted B-vitamin supplementation (folic acid and vitamin B12) reliably lower plasma homocysteine levels by 20% to 30% in affected individuals.
• Correcting these deficiencies is crucial to prevent cognitive decline, peripheral neuropathy, and megaloblastic anemia; however, large-scale clinical trials indicate that lowering homocysteine through supplementation does not significantly reduce the risk of major cardiovascular events or overall mortality.

Bottom line

• Vitamin B12 and folate are mandatory cofactors for the remethylation of homocysteine to methionine; deficiency disrupts this junction, causing hyperhomocysteinemia and depleted cellular methylation capacity, which can be corrected via appropriate supplementation.